{"id":81044,"date":"2026-05-26T12:05:14","date_gmt":"2026-05-26T12:05:14","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/peptide-therapy-websites-tout-benefits-nearly-4x-more-often-than-safety-details-100-page-audit-finds\/"},"modified":"2026-05-26T12:05:14","modified_gmt":"2026-05-26T12:05:14","slug":"peptide-therapy-websites-tout-benefits-nearly-4x-more-often-than-safety-details-100-page-audit-finds","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/peptide-therapy-websites-tout-benefits-nearly-4x-more-often-than-safety-details-100-page-audit-finds\/","title":{"rendered":"Peptide Therapy Websites Tout Benefits Nearly 4x More Often Than Safety Details, 100-Page Audit Finds"},"content":{"rendered":"
\n

As FDA prepares to review several popular peptide-related substances, a new public-web audit across 25 states identifies a \u201cPeptide Transparency Gap\u201d in med spa, wellness, and longevity marketing.<\/em><\/p>\n

NEW YORK, NY, May 26, 2026 (GLOBE NEWSWIRE) — Peptide therapy websites are far more consistent at promoting potential benefits than explaining core safety details, according to a new 100-page public-web audit released by\u00a0MDConsultingNY<\/b><\/strong><\/a>, a New York-based digital marketing agency specializing in medical aesthetics, wellness, hormone, and longevity practices.<\/p>\n

The audit reviewed 100 publicly accessible peptide-therapy webpages from 100 distinct provider websites across 25 U.S. states<\/b><\/strong>. The review included med spas, wellness clinics, longevity clinics, hormone clinics, integrative practices, regenerative medicine practices, and aesthetic practices offering wellness-related services.<\/p>\n

The key finding: benefit language appeared on 100% of reviewed peptide therapy pages<\/b><\/strong>, while the average presence of four core safety\/transparency signals \u2014 FDA or regulatory status, product sourcing, self-sourcing warnings, and risk or side-effect discussion \u2014 was\u00a026.5%<\/b><\/strong>.<\/p>\n

That creates a 3.77x benefit-to-safety transparency imbalance<\/b><\/strong>.<\/p>\n

\u201cPeptide therapy is moving from niche biohacking into mainstream aesthetics and wellness,\u201d said the MDConsultingNY research team. \u201cThe problem is not simply that practices are discussing peptides. The problem is that many public webpages explain why patients might want them without equally clear information on FDA status, sourcing, risk, and medical supervision.\u201d<\/p>\n

Original audit findings<\/b><\/strong><\/p>\n

MDConsultingNY reviewed peptide-therapy pages across 25 states, with four public provider websites assigned to each state.<\/p>\n

The audit found:<\/p>\n